title: Longitudinal study of seroprevalence and serostability of 34 human papillomavirus types in European organ transplant recipients.
abstract: Organ transplant recipients (OTR) are at increased risk of cutaneous squamous cell carcinoma, which may be related to reactivation of human papillomavirus (HPV) infections. Measurement of change in HPV antibodies after transplantation would help to explore this hypothesis. We measured antibodies to 34 HPV types on up to six occasions over 18 months in 441 OTRs from five European countries. At baseline (mean 24 days after transplantation), 80% of all OTRs were seropositive to at least one HPV type. The beta HPV genus had the highest seroprevalence (45%). For most HPV genera baseline seroprevalence peaked between 40 and 59 years old. Most OTRs retained their serostatus over time and antibody levels were stable. Seroprevalence in immunosuppressed OTRs is stable in the 18 months immediately after transplantation. Thus there is no short-term evidence that immunosuppression leads to new or reactivated skin infection with HPV sufficient to induce antibodies.
authors.affiliation: Department of Population Health, Queensland Institute of Medical Research, Brisbane, Australia. Annika.Antonsson@qimr.edu.au
authors.forename: Annika
authors.initials: A
authors.lastname: Antonsson
authors.forename: Tim
authors.initials: T
authors.lastname: Waterboer
authors.forename: Jan N
authors.initials: JN
authors.lastname: Bouwes Bavinck
authors.forename: Damiano
authors.initials: D
authors.lastname: Abeni
authors.forename: Maurits
authors.initials: M
authors.lastname: de Koning
authors.forename: Sylvie
authors.initials: S
authors.lastname: Euvrard
authors.forename: Mariet C W
authors.initials: MC
authors.lastname: Feltkamp
authors.forename: Adèle C
authors.initials: AC
authors.lastname: Green
authors.forename: Catherine A
authors.initials: CA
authors.lastname: Harwood
authors.forename: Luigi
authors.initials: L
authors.lastname: Naldi
authors.forename: Ingo
authors.initials: I
authors.lastname: Nindl
authors.forename: Herbert J
authors.initials: HJ
authors.lastname: Pfister
authors.forename: Charlotte M
authors.initials: CM
authors.lastname: Proby
authors.forename: Wim G
authors.initials: WG
authors.lastname: Quint
authors.forename: Eggert
authors.initials: E
authors.lastname: Stockfleth
authors.forename: Sönke J
authors.initials: SJ
authors.lastname: Weissenborn
authors.forename: Michael
authors.initials: M
authors.lastname: Pawlita
authors.forename: Rachel E
authors.initials: RE
authors.lastname: Neale
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D002294:Carcinoma, Squamous Cell / Q000821:virology; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D027383:Papillomaviridae / Q000145:classification / Q000235:genetics / Q000276:immunology*; D030361:Papillomavirus Infections / Q000453:epidemiology* / Q000276:immunology / Q000821:virology; D012307:Risk Factors; D016036:Seroepidemiologic Studies; D012878:Skin Neoplasms / Q000821:virology; D019737:Transplants / Q000009:adverse effects / Q000821:virology*
chemical_list: D000914:Antibodies, Viral